Epilepsy and neurocysticercosis in an Andean community

International Journal of Epidemiology

Volumn 28, Issue 4, 1999, Pages 799-803

  Cruz, Marcelo E ^a,f   Schantz, Peter M ^b   Cruz, Ivan ^a   Espinosa, Patricio ^a   Preux, Pierre Marie ^c,d   Cruz, Antonio ^e   Benitez, Washington ^a   Tsang, Victor C w ^b   Fermoso, Julio ^e   Dumas, Michel ^c  

^a Unit of Neurosciences   (Ecuador)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c UNIVERSITÉ DE LIMOGES   (France)

^d School of Medicine   (France)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f Instituto de Neurociencias   (Ecuador)

Author keywords

Developing countries; Epilepsy; Neurocysticercosis; Neuroepidemiology

Indexed keywords

ANTICONVULSIVE AGENT; ANTIPARASITIC AGENT;

EPILEPSY; HEALTH SURVEY; MONITORING; RURAL SOCIETY;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMMUNITY; COMPUTER ASSISTED TOMOGRAPHY; DEVELOPING COUNTRY; ECUADOR; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROCYSTICERCOSIS; PRIORITY JOURNAL; PUBLIC HEALTH; RURAL POPULATION; SERODIAGNOSIS; TAENIA SOLIUM; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, HELMINTH; CHILD; CHILD, PRESCHOOL; CYSTICERCUS; ECUADOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEUROCYSTICERCOSIS; POPULATION SURVEILLANCE; PREVALENCE; RURAL POPULATION; TOMOGRAPHY, X-RAY COMPUTED;

CHILE;

EID: 0032790944     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/28.4.799     Document Type: Article

References (37)

1. Botero D, Tanowitz HB, Weiss LM, Wittner M. Taeniasis and cysticercosis. Infect Dis Clin North Am 1993;7:683-97.
2. World Health Organization. Guidelines for Surveillance Prevention and Control of Taeniasis/Cysticercosis. WHO document VPH/83.49, Geneva, 1983.
3. Preux PM, Melaku Z, Druet-Cabanac M et al. Cysticercosis and neurocysticercosis in Africa: current status. Neur Infect Epidemiol 1996; 1:63-68.
4. Latoviski N, Abrams G, Clark C et al. Cerebral cysticercosis. Neurology 1978;28:838-42.
5. White AC. Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis 1997;24:101-15.
6. Schantz PM, Moore AC, Muñoz JL et al. Neurocysticercosis in and Orthodox Jewish Community in New York City. N Engl J Med 1992; 327:692-95.
7. Guerrero F. Cisticercosis cerebral: hallazgos necrópsicos. Rev Ecuat Med Cien Biol 1965;3:142-50.
8. Sarti E, Schantz PM, Plancarte A et al. Prevalence and risk factors for Taenia solium taeniasis and cysticercosis in humans and pigs in a village in Morelos, Mexico. Am J Trop Med Hyg 1992;46:677-85.
9. Medina MT, Rosas E, Rubio-Donnadieu F, Sotelo J. Neurocysticercosis as the main cause of late-onset epilepsy in Mexico. Arch Intern Med 1990;150:325-27.
10. Garcia HH, Gilman R, Martinez M et al. Cysticercosis as a major cause of epilepsy in Peru. Lancet 1993;341:197-200.
11. Del Brutto OH, Santibanez R, Noboa CA et al. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 1992;42:389-92.
12. Schoenberg BS. Clinical neuroepidemiology in developing countries. Neuroepidemiology 1982;1:137-42.
13. Meneghini F, Rocca WA, Rigoletto F et al. Door-to-door prevalence study of neurological diseases in a Sicilian population. Neuroepidemiology 1991;10:70-85.
14. World Health Organization, Neurosciences Programme. Research Protocol for Measuring the Prevalence of Neurological Disorders in Developing Countries. Geneva: WHO, 1991.
15. Tsang VCW, Brand JA, Boyer AE. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 1989;159:50-59.
16. Herrera G. Diagnostico por Tomografia Axial Computarizada en neurocysticercosis. In: Garcia HH, Martinez SM (eds). Taeniasis/cysticercosis por T. solium. Lima: Ed Universo, 1996, pp.79-84.
17. Rodriguez-Carbajal J, Palacios G, Zee CH. Neuroradiology of cysticercosis of the central nervous system. In: Palacios E, Rodriguez-Carbajal J, Taveras J (eds). Cysticercosis of the Central Nervous System. Springfield: Charles C Thomas, 1983, pp.101-43.
18. Byrd SHE, Locke GE, Biggers S et al. The computed tomography appearance of cerebral cysticercosis in adults and children. Radiology 1982;144:819-23.
19. Cruz ME, Schoenberg BS, Ruales J et al. Pilot study to detect neurologic disease in Ecuador among a population with a high prevalence of endemic goiter. Neuroepidemiology 1985;4:108-11.
20. World Health Organization. Application of the International Classification of Diseases to Neurology. Geneva: WHO, 1987.
21. Cruz ME, Barberis P, Schoenberg BS. The epidemiology of epilepsy. In: Poeck K, Freund HJ, Ganshirt H (eds). Neurology. Proceedings of the XIII World Congress of Neurology. Berlin: Springer Verlag, 1986, pp.229-39.
22. Commission on epidemiology and prognosis, International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34:592-96.
23. Kramer LD, Locke G, Byrd SE. Cerebral cysticercosis: documentation of natural history by CT. Radiology 1989;171:459-62.
24. Cruz M, Cruz I, Horton J. Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation. Trans Roy Soc Trop Med Hys 1991;85:244-47.
25. Del Brutto AH, Wadia N, Dumas M et al. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neur Sci 1996;142: 1-6.
26. Schoenberg BS. Calculating confidence intervals for rates and ratios. Neuroepidemiology 1983;2:257-65.
27. Centers for Disease Control. Epi Info Version 5.01b, July, 1991. Atlanta, GA.
28. Cruz ME, Cruz I, Preux PM et al. Headache and cysticercosis in Ecuador, South America. Headache 1995;35:93-97.
29. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975;16:1-66.
30. Wilson M, Bryan RT, Fried JA et al. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 1991;164:1007-09.
31. Garcia HH, Gilman RH, Catacora M et al. Serologic evolution of neurocysticercosis patients after antiparasitic therapy. J Infect Dis 1997; 175:486-89.
32. De Ghetaldi LD, Norman RM, Couville AW. Cerebral cysticercosis treated biphasically with dexamethazone and praziquantel. Ann Intern Med 1983;99:179-81.
33. Cruz I, Cruz ME, Carrasco F, Horton J. Neurocysticercosis: optimal dose treatment with albendazole. J Neurol Sci 1995;133:152-54.
34. Vazquez V, Sotelo J. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med 1992;327:696-701.
35. Del Brutto AH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994;44:1706-09.
36. Cruz M, Davis A, Dixon H, Pawlowski ZS, Proano J. Operational studies on the control of Taenia solium taeniasis/cysticercosis in Ecuador. Bull World Health Organ 1989;67:401-07.
37. Schantz PM, Cruz M, Sarti E, Pawolwski Z. Potential eradicability of taeniasis and cysticercosis. Bull Pan Am Health Organ 1993;27:397-401.